Laurus Labs to buy 60% of Canada's Galenvs Sciences for USD 3.75 million
Laurus Labs told the National Stock Exchange it will invest USD 3.75 million for a combined 60% of Galenvs Sciences, a Montreal-based oligonucleotide research and development company.
Key points
- Laurus Labs said in a filing with the National Stock Exchange that it will take a combined 60% stake in Canada's Galenvs Sciences Inc. for USD 3.75 million in cash.
- USD 2.75 million buys new shares equal to 44% of Galenvs and USD 1.00 million buys existing shares equal to 16%.
- The company expects the deal to close in the current financial year, subject to customary closing conditions, and says no government approval is needed.
Laurus Labs Limited said in a filing with the National Stock Exchange on 30 October 2026 that it will acquire a combined 60% stake in Galenvs Sciences Inc., a company based in Montreal, Canada, for USD 3.75 million in cash. The decision was taken at a board meeting held on 29 October 2026.
What Happened
The company's filing says the deal has two parts. First, Laurus Labs will subscribe to 8,092,857 new common shares of Galenvs for USD 2.75 million, which would be 44% of Galenvs on a diluted basis after the issue. Second, it will buy 2,942,857 existing common shares from a founder shareholder for USD 1.00 million, equal to 16% on the same basis. Laurus Labs holds no shares in Galenvs today.
The filing describes Galenvs as a precision contract research and development organisation, also called a CRO or CDMO, that specialises in custom oligonucleotide synthesis and magnetic-nanoparticle technologies for the diagnostics and therapeutics markets. Oligonucleotides are short strands of genetic material used in some medicines and tests. Galenvs was incorporated on 26 September 2016, has research and laboratory facilities in Montreal and operates across North America.
The company's remarks give the target's most recent figures in Canadian dollars: turnover of CAD 1.65 million, a loss after tax of CAD 0.23 million and a net worth of negative CAD 0.26 million. The filing says the deal is not a related party transaction, that the promoters and group companies have no interest in Galenvs, and that it is done at arm's length. It says no government or regulatory approval is required and the deal is not in tranches.
Laurus Labs expects to complete the transaction in the current financial year, subject to customary closing conditions and agreements.
What It Means
According to the filing, Galenvs would handle discovery, lead optimisation and pre-clinical process development, and pass the technology to Laurus Labs for clinical trial phases and for scaling up to commercial production. The company says it would gain a research pipeline arm for oligonucleotides, process know-how and a growth opportunity in North America.
The structured filing lists some of these amounts in rupee fields that do not match the amounts in the company's own remarks; this report follows the remarks, which state the amounts in US and Canadian dollars. The filing does not say what the deal would add to Laurus Labs' revenue.
Oquilia Data: Laurus Labs Ltd. (NSE: LAURUSLABS)
| Close, 29 Oct 2026 | Rs 2,244.00 (+2.85% on the day) |
|---|---|
| Return 1M / 3M / 6M / YTD / 1Y | +13.39% / +25.98% / +102.87% / +102.53% / +133.34% |
| Against Nifty 50, 1M / 3M / YTD | +12.42 / +31.39 / +114.75 points |
| 52-week closing high / low | Rs 2,244.00 (29 Oct 2026) / Rs 930.20 (1 Feb 2026) |
| Turnover, 20-session average | Rs 330.33 cr; 48.5% delivered; latest volume 1.8x |
Closes adjusted for splits and bonuses; returns exclude dividends. Facts from NSE's files, not investment advice.
Full record: Laurus Labs share price on Oquilia
Source: Company filing on NSE
Sources & Citations
- Company filing on NSE — National Stock Exchange of India